Medical Business

Features

The Medical Business develops BNCT (Boron Neutron Capture Therapy) which is a major breakthrough in cancer treatment in the world.
BNCT is one form of particle radiation therapy. With it, cancer cells absorb a boron drug which has been infused into the body. The affected area is irradiated with a neutron beam from outside the body. The nuclear fission reaction of the boron (boron-10) and the thermal neutron that occurs at that time is used to selectively destroy the cancer cells.
With conventional radiation therapy, there was a risk of side effects due to the damage to normal cells. With BNCT, only cancer cells can be destroyed with pinpoint accuracy and high expectations are placed on it as a form of therapy with a low impact on the body.
Technology to generate enriched boron (boron-10) is indispensable in the manufacturing of boron drugs. Stella Chemifa possesses the only boron-10 enriched plant in Japan. Using our own technology, we are focusing our energies toward realizing the cancer therapy unique in the world.
At the current time, our subsidiary, Stella Pharma is conducting clinical trials utilizing boron drugs developed jointly with Osaka Prefecture University and a medical accelerator irradiation system for BNCT made by Sumitomo Heavy Industries, Ltd.
We are proceeding with our work, aiming to receive approval as soon as possible for the benefit of saving even a single irreplaceable life.

Great expectations of the BNCT (Boron Neutron Capture Therapy)

medical_bnct.png

Involvement in Cancer Diagnostic Technology

We are engaged in developing new PET (Positron Emission Tomography) drugs utilized in PET diagnosis, technology useful in the early detection of cancer.
These drugs enable detection of brain tumors which are currently difficult to detect, so we are aiming to create a system that combines PET diagnosis with BNCT to detect and treat cancer in its early stages.

Stella Pharma Corporation's official website

Stella Pharma Corporation's official website